Madjd Z - Search Results

1

Loss of CD55 is associated with aggressive breast tumors.

Madjd Z, Durrant LG, Bradley R, Spendlove I, Ellis IO, Pinder SE. Madjd Z, et al. Clin Cancer Res. 2004 Apr 15;10(8):2797-803. doi: 10.1158/1078-0432.ccr-1073-03. Clin Cancer Res. 2004. PMID: 15102687

2

Efficacy of Whole Cancer Stem Cell-Based Vaccines: A Systematic Review of Preclinical and Clinical Studies.

Hashemi F, Razmi M, Tajik F, Zöller M, Dehghan Manshadi M, Mahdavinezhad F, Tiyuri A, Ghods R, Madjd Z. Hashemi F, et al. Among authors: madjd z. Stem Cells. 2023 Mar 17;41(3):207-232. doi: 10.1093/stmcls/sxac089. Stem Cells. 2023. PMID: 36573273

3

Novel Monoclonal Antibodies Specific for Human Ki67 and P53 Tumor Markers in Breast Cancer Tissue Samples.

Hassanzadeh Makoui M, Mobini M, Khoshnoodi J, Bahadori T, Golsaz-Shirazi F, Moradi Tabriz H, Madjd Z, Jeddi-Tehrani M, Zarnani AH, Amiri MM, Shokri F. Hassanzadeh Makoui M, et al. Among authors: madjd z. Iran J Immunol. 2023 May 31;20(2):177-189. doi: 10.22034/iji.2023.96926.2469. Epub 2023 May 7. Iran J Immunol. 2023. PMID: 37149778 Free article.

4

Heterotypic tumor spheroids: a platform for nanomedicine evaluation.

Vakhshiteh F, Bagheri Z, Soleimani M, Ahvaraki A, Pournemat P, Alavi SE, Madjd Z. Vakhshiteh F, et al. Among authors: madjd z. J Nanobiotechnology. 2023 Aug 2;21(1):249. doi: 10.1186/s12951-023-02021-y. J Nanobiotechnology. 2023. PMID: 37533100 Free PMC article. Review.

5

Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells.

Choupani E, Madjd Z, Saraygord-Afshari N, Kiani J, Hosseini A. Choupani E, et al. Among authors: madjd z. PLoS One. 2022 Dec 22;17(12):e0279522. doi: 10.1371/journal.pone.0279522. eCollection 2022. PLoS One. 2022. PMID: 36548336 Free PMC article.

6

Loss of CD59 expression in breast tumours correlates with poor survival.

Madjd Z, Pinder SE, Paish C, Ellis IO, Carmichael J, Durrant LG. Madjd Z, et al. J Pathol. 2003 Aug;200(5):633-9. doi: 10.1002/path.1357. J Pathol. 2003. PMID: 12898600

7

Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?

Madjd Z, Durrant LG, Pinder SE, Ellis IO, Ronan J, Lewis S, Rushmere NK, Spendlove I. Madjd Z, et al. Cancer Immunol Immunother. 2005 Feb;54(2):149-56. doi: 10.1007/s00262-004-0590-0. Epub 2004 Sep 16. Cancer Immunol Immunother. 2005. PMID: 15378282 Free PMC article.

8

Total loss of MHC class I is an independent indicator of good prognosis in breast cancer.

Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Madjd Z, et al. Int J Cancer. 2005 Nov 1;117(2):248-55. doi: 10.1002/ijc.21163. Int J Cancer. 2005. PMID: 15900607

9

Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis.

Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG. Watson NF, et al. Among authors: madjd z. Int J Cancer. 2006 Jan 1;118(1):6-10. doi: 10.1002/ijc.21303. Int J Cancer. 2006. PMID: 16003753

10

Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients.

Watson NF, Madjd Z, Scrimegour D, Spendlove I, Ellis IO, Scholefield JH, Durrant LG. Watson NF, et al. Among authors: madjd z. World J Surg Oncol. 2005 Jul 19;3:47. doi: 10.1186/1477-7819-3-47. World J Surg Oncol. 2005. PMID: 16029489 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

171 results

Search Page

Filters